Physician profile
Bobby Nibhanupudy
NPI 1407956725
$2,924.47
in general payments reported to CMS, 2019-2025
24 companies · $316 in 2025
The $316 reported for 2025 was less than what a typical Transplant Surgery provider received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $758 · 2020: $360 · 2021: $231 · 2022: $130 · 2023: $108 · 2024: $1,022 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $966 · Travel and Lodging: $479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $966.02 |
| Travel and Lodging | $479.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xvivo Perfusion INC. | $934.30 | 2024 | Xvivo Perfusion System (Xps) |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $324.73 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $314.61 | 2019-2022 | |
| Veloxis Pharmaceuticals, INC. | $230.01 | 2019-2023 | Envarsus |
| Intercept Pharmaceuticals, INC. | $178.83 | 2020-2024 | Ocaliva |
| Abbvie INC. | $124.98 | 2025 | |
| Ethicon US, LLC | $105.70 | 2019-2022 | |
| Tetraphase Pharmaceuticals, INC. | $105.26 | 2019 | |
| Shionogi INC | $91.61 | 2019 | |
| Integra Lifesciences Corporation | $91.04 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $57.69 | 2025 | |
| Merck Sharp & Dohme LLC | $56.18 | 2023-2024 | Prevymis, Dificid, Zerbaxa |
| Dynavax Technologies Corporation | $55.18 | 2020-2022 | |
| Gilead Sciences, INC. | $38.45 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.62 | 2020-2024 | Livtencity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kamada LTD. | $34.00 | 2025 | |
| Alexion Pharmaceuticals, INC. | $29.69 | 2025 | Ultomiris |
| Novo Nordisk INC | $25.35 | 2025 | Wegovy |
| Organox LTD | $24.57 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $18.68 | 2020 | |
| Vifor Pharma, INC. | $18.11 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.36 | 2023 | Jardiance |
| Intra-Sana Laboratories | $12.52 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bobby Nibhanupudy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.